Patrick Christ

Patrick Christ

Auto-generated profile, based on publicly available information

Patrick Christ

Research Division, Federal Institute for Drugs and Medical Devices, Bonn, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DDDiana Dubrall
Diana Dubrall
PCPatrick Christ
Patrick Christ
SDSeverin Domgörgen
Severin Domgörgen
MSMatthias Schmid
Matthias Schmid
BSBernhardt Sachs
Bernhardt Sachs
The aim of this study was to identify factors associated with the completeness of spontaneous reports of adverse drug reactions (ADR) from different reporter types. We analysed 69,976 spontaneous ADR reports from physicians, 42,396 from pharmacists and 121,144 from consumers. The adjusted vigiGrade completeness score for ADR reports from EudraVigilance was used to evaluate the completeness of information provided in the structured format of each ADR report. Mean values of the vigiGrade completeness scores were calculated for various factors such as age, sex, receive year, seriousness and causal relationship. For all three reporters, the completeness of the ADR reports referring to older patients and children/ adolescents was lower than for middle-aged patients. Furthermore, generally poorly documented reports often included more than one suspected/interacting drug or no information on the patients’ sex. Additionally, ADR reports with an at least possible causal relationship were more completely documented than those with a not assessable causal relationship in a subset of 479 ADR individually assessed reports. Differences between the reporters were only observed regarding seriousness criteria and receive year. The missing of certain information parameters in ADR reports from all three reporter types may serve as indicators for a poorer overall completeness of documentation.

21 November 2023 in Drug Safety
Verified
Journal Article
Open access
PDF file
PCPatrick Christ
Patrick Christ
DDDiana Dubrall
Diana Dubrall
MSMatthias Schmid
Matthias Schmid
BSBernhardt Sachs
Bernhardt Sachs
Introduction Adverse drug reactions (ADRs) can be reported by Health Care Professionals (HCPs; e.g., physicians, pharmacists) and non-Health Care Professionals (non-HCPs; e.g., consumers). Previous studies investigating differences between reports from HCPs and non-HCPs rarely considered the completeness of information provided. In addition, they mostly did not distinguish between physicians and pharmacists or were performed years ago. The aim of our study was to analyse and compare the completeness of information provided in reports from physicians, pharmacists and consumers from Germany in a more recent dataset. Materials and methods We analysed all spontaneous reports from Germany received between 2018 and 2021 in the ADR database EudraVigilance exclusively reported by physicians (n = 69,976), pharmacists (n = 42,396) or consumers (n = 121,144). Demographical parameters of the patients were analysed descriptively. Completeness of reports was evaluated applying an established score (vigiGrade). Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using logistic regression analysis in order to identify report, patient, drug or ADR-specific information provided more often in reports from physicians, pharmacists or consumers. Results Within the study period the number of reports per year by physicians and pharmacists decreased steadily, while an opposite trend was observed for consumer reports. The proportion of female patients was higher in reports from pharmacists (64.4%) and consumers (64.8%) compared to those from physicians (55.3%). On average, patients in reports from pharmacists (58.7) were older compared to those from physicians (53.5) and consumers (52.6). As an example for the presence of specific information, the time to onset of the ADR could be calculated more often in consumer compared to physician (OR 1.9 [1.8–1.9]) and pharmacist reports (OR 1.7 [1.6–1.7]). In contrast, pharmacist (OR 0.5 [0.4–0.5]) and consumer (OR 0.5 [0.5–0.5]) reports included the indication of the suspected drug less often than physician reports. Physician reports on average (mean = 0.5) were slightly more complete according to the vigiGrade score compared to reports from consumers (mean = 0.4) and pharmacists (mean = 0.4). Conclusion The ADR reports from consumers were comparable with regard to the completeness score with those from physicians and pharmacists underlining their value. Differences in completeness of specific information between the reporter types were found, suggesting that a common reporting of interactions between the three reporters may further improve the completeness of ADR reports. Furthermore, stratified analysis of ADR reports per reporter type may be helpful for certain objectives in scientific research.

12 November 2022 in Pediatric Drugs
Verified
Journal Article
Open access
PDF file
SLSarah Leitzen
Sarah Leitzen
DDDiana Dubrall
Diana Dubrall
ITIrmgard Toni
Irmgard Toni
JSJulia Carolin Stingl
Julia Carolin Stingl
PCPatrick Christ
Patrick Christ
BSBernhardt Sachs
Bernhardt Sachs
Background Adverse drug reactions (ADRs) and medication errors in children may result from a lack of appropriate drugs, dosages, and pharmaceutical forms. In addition, children may respond differently to drugs than adults. Reporting of ADRs in the pediatric population is therefore of importance in order to increase the amount of safety data. However, different methodological approaches are used to collect ADRs. Objective The aim of the present study was to analyze whether there were differences in the ADRs collected in the KiDSafe project (845 ADR reports) compared with the spontaneous ADR reports sent to EudraVigilance (697 reports) in the same time period. The strengths and limitations of these two different approaches should be discussed. Methods The same inclusion criteria were applied for the systematically collected ADRs in the KiDSafe project and the spontaneous reports from EudraVigilance, and only reports of ADRs coded with hospitalization were considered. In both datasets, the number of reports (related to number of hospitals), their documentation quality (VigiGrade), causal relationship (World Health Organization-Uppsala Monitoring Centre [WHO-UMC] criteria), most frequently reported drugs and ADRs, demographical parameters of the patients, reported medical histories, and the seriousness of ADR reports were analyzed descriptively. The results of the two analyses were compared. Results There was considerable underreporting of ADRs via the spontaneous reports (0.4 reports per hospital; 697/1902) compared with 70.4 reports per hospital (845/12) in the systematically collected KiDSafe reports. Documentation quality assessment yielded similar results in both datasets. Among the 10 most frequently reported drugs, anticonvulsants such as levetiracetam (6.6%), valproic acid (5.6%), oxcarbazepine (3.6%), and lamotrigine (3.4%) were mainly reported in the KiDSafe reports, while in the EudraVigilance reports, mite allergen extract (4.4%) and allergens (3.6%) were preferentially reported. Seizures were the most frequently reported clinically specific ADRs in the KiDSafe reports, whereas anaphylactic reactions and urticaria were prominent in the spontaneous reports from EudraVigilance. Notably, the proportion of reports referring to medication errors and other medication safety related issues were more prominent in KiDSafe than in the spontaneous reports (27.8% vs. 12.6% and 46.0% vs. 29.0%, respectively). Conclusion In general, reports from both data sources contributed to the identification of ADRs and dedicated issues related to drug therapy. However, these differed by nature and strength of the signal, likely due to the characteristics of the individual method. A combined approach could likely compensate for limitations inherent to the single approaches, but will most likely only be applied to dedicated pharmacovigilance topics or research objectives.

28 November 2023 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PCPatrick Christ
Patrick Christ
DDDiana Dubrall
Diana Dubrall
KJKatja S Just
Katja S Just
BLBritta Lewke
Britta Lewke
MBMaike Below
Maike Below
BSBernhardt Sachs
Bernhardt Sachs
Aims: Adverse drug reactions (ADRs) are known to show sex‐specific differences in occurrence and phenotype. The aim of this study was to analyse sex‐specific differences in ADR–drug combinations that required hospitalization based on two different datasets.Methods: We performed a complementary analysis of (i) spontaneously reported (n = 12 564, female = 51.7%) and (ii) systematically collected ADR reports from a prospective multicentre observational study (ADRED, n = 2355, female = 48.2%) from Germany in the ADR database EudraVigilance (EV). Both datasets were analysed separately concerning the suspected drugs, ADRs and ADR–drug combinations more frequently reported for females or males by calculating reporting odds ratios (ROR) with 95% confidence intervals. ADR–drug combinations more frequently reported for either females or males in EV reports were related to prescription data. Finally, the results from both datasets were discussed with regard to their (dis‐)concordance.Results: In both datasets, some antineoplastic agents and nervous system drugs were found to be reported more often for females than males (RORs ranging from 1.5 [1.1–2.1] for quetiapine in spontaneous reports to 41.3 [13.1–130.0] for trastuzumab in spontaneous reports). ADRs of the respiratory system, and haemorrhages were described predominantly for males in both datasets. In spontaneous reports the ADR–drug combination self‐injurious behaviour–quetiapine was more often reported for females without and with consideration of drug prescriptions (ROR: 3.8 [1.3–11.0]). Quetiapine and psychiatric disorders (superordinate level) was exclusively reported for females in ADRED reports.Conclusions: Our results can contribute to raise awareness and further knowledge regarding sex‐specific ADRs. The findings require further in‐depth investigation.

21 October 2026 in Drug Safety
Verified
Journal Article
Open access
PDF file
DDDiana Dubrall
Diana Dubrall
PCPatrick Christ
Patrick Christ
DLDennis Lex
Dennis Lex
RHRobert Hoffmann
Robert Hoffmann
TGThomas Grüger
Thomas Grüger
BSBernhardt Sachs
Bernhardt Sachs
Introduction In the absence of a gold standard for assessing the completeness of spontaneous adverse drug reaction (ADR) reports, most studies have relied on assessing the proportion of reports containing information on predefined categories. The same principle applies to the Vigi4Eudra-score, which can be used to analyse the completeness of ADR reports from EudraVigilance. Moreover, ADR reports with a high level of information provided may be more useful in pharmacovigilance practice. The first aim of our study was to further develop the already existing Vigi4Eudra-score by modifying its penalties and by adding additional relevant categories (= EudraScore). The second aim was to assess whether the EudraScore performed better than the Vigi4Eudra-score to identify reports with at least a possible causal relationship as “well documented”. Methods An expert panel was established comprising assessors from the pharmacovigilance and the research department of the German Federal Institute for Drugs and Medical Devices, with many years of experience in the assessment of ADR reports. Based on expert consensus, the Vigi4Eudra-score was modified by adapting existing categories and incorporating additional causality-relevant criteria, resulting in the EudraScore. A use case was conducted to compare the values calculated using the EudraScore with those obtained from the Vigi4Eudra-score. The performance of both scores in identifying reports with an “at least possible” causal relationship as “well documented” was evaluated by calculating sensitivity and specificity. Results Compared to the Vigi4Eudra-score, some penalties were adjusted for the EudraScore, with reduced penalties for missing country of origin and drug dose (from 10 to 5%) and an increased penalty for the absence of a free-text description (from 10 to 30%) when information on time to onset and ADR outcome is missing. The categories patient’s history (+ 10%), concomitant drugs (+ 10%), rechallenge/dechallenge/action taken with the drug (+ 10%), and seriousness (+ 5%) were added as a bonus score. Finally, the bonus score was weighed by the respective penalty score. In the use case, most reports received higher values with the EudraScore compared to the Vigi4Eudra-score, although the differences were generally small (≤ 0.1). The categories drug dose, seriousness, and patient’s history mostly led to the observed differences. Although the completeness does not directly reflect the strength of the causal association, the EudraScore received a higher sensitivity (0.347 [0.293–0.405]) compared to the Vigi4Eudra-score (0.245 [0.197–0.299], p < 0.001) and a negligibly lower specificity (EudraScore: 0.907 [0.860–0.940], Vigi4Eudra-score: 0.932 [0.889–0.959], p = 0.07) for identifying reports with an “at least possible” causal relationship as “well documented”. Conclusion Although the sensitivity was rather low, the EudraScore appears to be more suitable for the prioritisation of ADR reports of higher relevance than the Vigi4Eudra-score. Additionally, further development of the EudraScore to not only assess the presence of information but also information quality could add substantial value.

11 June 2026 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
DDDiana Dubrall
Diana Dubrall
SDSeverin Domgörgen
Severin Domgörgen
PCPatrick Christ
Patrick Christ
MBMaike Below
Maike Below
MSMatthias Schmid
Matthias Schmid
BSBernhardt Sachs
Bernhardt Sachs
The absolute number of spontaneous adverse drug reaction (ADR) reports increased in the past in several national and international ADR databases. However, in most studies drug exposure was not considered. Our study aimed to evaluate the number of ADR reports from Germany in relation to the number of patients with outpatient drug prescriptions stratified by sex, age groups, seriousness, and reporter types (physician versus consumer). Therefore, 407 882 spontaneous ADR reports from Germany, after exclusion of ADR reports related to vaccines, intentional misuses and accidental exposure, submitted between 01.01.2012 and 31.12.2021 were analyzed. The annual numbers of patients with at least one outpatient drug prescription were provided by the Central Research Institute for Ambulatory Health Care in Germany. Reporting rates per year were calculated by dividing the annual number of spontaneous ADR reports by the annual number of patients with at least one outpatient drug prescription. Between 2012 and 2021 (2.4‐fold), and strikingly between 2017 and 2018 (2.2‐fold), the annual reporting rate increased. This increase appears to be primarily driven by non‐serious ADR reports submitted by consumers (32.5‐fold increase), whereas reporting rates for serious ADRs and for reports submitted by physicians remained stable. Furthermore, the rise of non‐serious ADR reports from consumers was particularly apparent for females aged 12–17 and 18–64 years. Overall, the observed increase of non‐serious ADR reports is most likely related to changes in reporting obligations for pharmaceutical companies. Our study suggests that females might report ADRs more frequently.